This application describes applications and industrial products including pertuzumab, the best-in-class inhibitor of dimerization of HER2. In particular, the application relates to methods for extending progression-free survival in a population of patients with HER2-positive breast cancer； the combination of two antibodies against HER2 for the treatment of HER2-positive cancer without increasing cardiotoxicity； treatment of early-stage HER2-positive breast cancer； for treating HER2-positive cancer by co-administering a mixture of pertuzumab and trastuzumab from a single intravenous bag； treatment of HER2-positive metastatic gastric cancer； treatment of HER2-positive breast cancer with pertuzumab, trastuzumab and vinorelbine； treatment of HER2-positive breast cancer with pertuzumab, trastuzumab, and an aromatase inhibitor, and treatment of ovarian cancer with low levels of HER3, primary peritoneal malignant tumor, or malignant tumor of the fallopian tubes. The application also describes an industrial product that includes a vial with pertuzumab inside and a package insert that provides safety data and / or performance data； a method of manufacturing an industrial product and a method for ensuring the safe and effective use of pertuzumab relating to the product. In addition, the application describes a package for intravenous (IV) administration, containing a stable mixture of pertuzumab and trastuzumab, suitable for administration to a patient with cancer.Настоящая заявка описывает применение и промышленные изделия, включающие пертузумаб, наилучший в своем классе ингибитор димеризации HER2. В частности, заявка относится к способам для продления выживаемости без прогрессирования в популяции пациентов с HER2-положительным раком молочной железы； к сочетанию двух антител против HER2 для лечения HER2-положительного рака без повышения кардиотоксичности； к лечению ранней стадии HER2-положительного рака молочной железы； к лечению HER2-положительного рака путем совместного вв
